The role of negative symptoms in the context of cognitive remediation for schizophrenia

Schizophrenia Research

Volumn 150, Issue 1, 2013, Pages 58-63

  Farreny, Aida ^a   Aguado, Jaume ^a,b   Ochoa, Susana ^a   Haro, Josep Maria ^a   Usall, Judith ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cognitive remediation; Functional outcome; Mediated effects; Negative symptoms; Neurocognition; Schizophrenia

Indexed keywords

ADULT; ARTICLE; BEHAVIORAL ASSESSMENT OF THE DYSEXECUTIVE SYNDROME; CLINICAL EFFECTIVENESS; COGNITIVE REMEDIATION; CONTROLLED STUDY; EXECUTIVE FUNCTION; FEMALE; HUMAN; LEISURE; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; OUTPATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOLOGIC ASSESSMENT; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT RESPONSE;

COGNITIVE REMEDIATION; FUNCTIONAL OUTCOME; MEDIATED EFFECTS; NEGATIVE SYMPTOMS; NEUROCOGNITION; SCHIZOPHRENIA;

ADOLESCENT; ADULT; COGNITION DISORDERS; COGNITIVE THERAPY; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884167874     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.08.008     Document Type: Article

References (40)

1. American Psychiatric Association (APA), López-Ibor, J.J., Valdés, M. (dir.), 2002. DSM-IV-TR: Manual diagnóstico y estadístico de los trastornos mentales. Texto revisado. Masson, Barcelona.
2. Ballesteros-Rodríguez J., Martínez-Peña L., Martín-Carrasco M., Ibarra-Gandiaga N., Bulbena-Vilarrasa A. Assessment of the life skills profile and the brief psychiatric rating scale as predictors of the length of psychiatric hospitalization. Actas Esp. Psiquiatr. 2002, 30:225-232.
3. Bell M.D., Mishara A.L. Does negative symptom change relate to neurocognitive change in schizophrenia? Implications for targeted treatments. Schizophr. Res. 2006, 81:17-27.
4. Bowie C.R., Leung W.W., Reichenberg A., McClure M.M., Patterson T.L., Heaton R.K., Harvey P.D. Predicting schizophrenia patient's real-world behavior with specific neuropsychological and functional capacity measures. Biol. Psychiatry 2008, 63:505-511.
5. Bowie C.R., Depp C., McGrath J.A., Wolyniec P., Mausbach B.T., Thornquist M.H., Luke J., Patterson T.L., Harvey P.D., Pulver A.E. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am. J. Psychiatry 2010, 167:1116-1124.
6. Farreny A., Aguado J., Ochoa S., Huerta-Ramos E., Marsà F., López-Carrilero R., Carral V., Haro J.M., Usall J. REPYFLEC cognitive remediation group training in schizophrenia. Looking for an integrative approach. Schizophr. Res. 2012, 142:137-144.
7. Fernández de Larrinoa P., Bulbena A., Domínguez A.I. Estudio de fiabilidad, validez y consistencia interna de la escala LSP (LifeSkillsProfile). Perfil de habilidades de la vida cotidiana. Actas Luso Esp. Neurol. Psiquiatr. Cienc. Afines 1992, 20:71-75.
8. Foussias G., Remington G. Negative symptoms in schizophrenia: avolition and Occam's Razor. Schizophr. Bull. 2010, 36:359-369.
9. Frith C.D. The cognitive neuropsychology of schizophrenia 1992, Lawrence Erlbaum Associates, Sussex.
10. Fritz M.S., MacKinnon D.P. Required sample size to detect mediated effect. Psychol. Sci. 2007, 18:233-239.
11. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26:119-136.
12. Green M.F., Hellemann G., Horan W.P., Lee J., Wynn J.K. From perception to functional outcome in schizophrenia. Modeling the role of ability and motivation. Arch. Gen. Psychiatry 2012, 69:1216-1224.
13. Greenwood K.E., Landau S., Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr. Bull. 2005, 31:910-921.
14. Greenwood K.E., Morris R., Sigmundsson T., Landau S., Wykes T. Executive functioning in schizophrenia and the relationship with symptom profile and chronicity. J. Int. Neuropsychol. Soc. 2008, 14:782-792.
15. Grynszpan O., Perbal S., Pelissolo A., Fossati P., Jouvent R., Dubal S., Pérez-Díaz F. Efficacy and specificity of computer-assisted cognitive remediation in schizophrenia: a meta-analytical study. Psychol. Med. 2011, 41:163-173.
16. Harvey P.D. Assessment of everyday functioning in schizophrenia: implications for treatments aimed at negative symptoms. Schizophr. Res. 2013, 10.1016/j.schres.2013.04.022.
17. Harvey P.D., Koren D., Reichenberg A., Bowie C.R. Negative symptoms and cognitive deficits: what is the nature of their relationship?. Schizophr. Bull. 2006, 32:250-258.
18. Kay S.R., Fiszbeln A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
19. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32:214-219.
20. Klingberg S., Wölwer W., Engel C., Wittorf A., Herrlich J., Meisner C., Buchkremer G., Wiedemann G. Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. Schizophr. Bull. 2011, 37:S98-S110.
21. Kurtz M.M., Moberg P.J., Ragland J.D., Gur R.C., Gur R.E. Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1-and 4-year prospective study. Schizophr. Bull. 2005, 31:167-174.
22. Lin C.H., Huang C.L., Chang Y.C., Chen P.W., Lin C.Y., Tsai G.E., Lane H.Y. Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia. Schizophr. Res. 2013, 146:231-237.
23. Lipkovich I.A., Deberdt W., Csernansky J.G., Sabbe B., Keefe R.S.E., Kollack-Walker S. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24weeks of antipsychotic drug therapy. BMC Psychiatry 2009, 9:44. 10.1186/1471-244X-9-44.
24. MacKinnon D.P. Introduction to statistical mediation analysis 2008, Lawrence Erlbaum Associates, New York.
25. McGurk S.R., Twamley E.W., Sitzer D.I., McHugo G.J., Mueser K.T. A meta-analysis of cognitive remediation in schizophrenia. Am. J. Psychiatry 2007, 164:1791-1802.
26. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 2005, 162:495-506.
27. Penadés R., Catalán R., Puig O., Masana G., Pujol N., Navarro V., Guarch J., Gastó C. Executive function needs to be targeted to improve social functioning with Cognitive Remediation Therapy (CRT) in schizophrenia. Psychiatry Res. 2010, 177:41-45.
28. Peralta V., Cuesta M.J. Validación de la Escala de los Síndromes positivo y negativo (PANSS) en una muestra de esquizofrénicos españoles. Actas Luso Esp. Neurol. Psiquiatr. Cienc. Afines 1994, 22:171-177.
29. Rosen A., Hadzi-Pavlovic D., Parker G. The Life Skills Profile: a measure assessing function and disability in schizophrenia. Schizophr. Bull. 1989, 15:325-337.
30. Schermelleh-Engel K., Moosbrugger H., Müller H. Evaluating the fit of structural equation models: tests of significance and descriptive goodness-of-fit measures. Methods Psychol. Res. 2003, 8:23-74.
31. Ventura J., Hellemann G.S., Thames A.D., Koellner V., Neuchterlein K.H. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr. Res. 2009, 113:189-199.
32. Ventura J., Wood R.C., Hellemann G.S. Symptom domains and neurocognitive functioning can help differentiate social cognitive processes in schizophrenia. Schizophr. Bull. 2013, 39:102-111.
33. Villalta-Gil V., Vilaplana M., Ochoa S., Haro J.M., Dolz M., Usall J., Cervilla J., NEDENA Group Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia patients?. Schizophr. Res. 2006, 87:246-253.
34. Vita A., De Peri L., Barlati S., Cacciani P., Deste G., Poli R., Agrimi E., Cesana B.M., Sacchetti E. Effectiveness of different modalities of cognitive remediation on symptomatological, neuropsychological, and functional outcome domains in schizophrenia: a prospective study in a real-world setting. Schizophr. Res. 2011, 133:223-231.
35. Wallwork R.S., Fortgang R., Hashimoto R., Weinberger D.R., Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr. Res. 2012, 137:246-250.
36. Wilson B.A., Alderman N., Burgess P.W., Emslie H., Evans J.J. Behavioural Assessment of the Dysexecutive Syndrome 1996, Thames Valley Test Company, Bury St. Edmunds.
37. Wykes T., Spaulding W.D. Thinking about the future cognitive remediation therapy-what works and could we do better?. Schizophr. Bull. 2011, 37:S80-S90.
38. Wykes T., Newton E., Landau S., Rice C., Thompson N., Frangou S. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial. Schizophr. Res. 2007, 94:221-230.
39. Wykes T., Huddy V., Cellard C., McGurk S., Czbor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am. J. Psychiatry 2011, 168:472-485.
40. Wykes T., Reeder C., Huddy V., Taylor R., Wood H., Ghirasim N., Kontis D., Landau S. Developing models of how cognitive improvements change functioning: mediation, moderation and moderated mediation. Schizophr. Res. 2012, 138:88-93.